Focused On-demand Library for Claudin-10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P78369

UPID:

CLD10_HUMAN

Alternative names:

Oligodendrocyte-specific protein-like

Alternative UPACC:

P78369; Q6IBF9; Q96N78

Background:

Claudin-10, also known as Oligodendrocyte-specific protein-like, is pivotal in tight junction-specific obliteration of the intercellular space, offering calcium-independent cell-adhesion activity. It regulates paracellular epithelia permeability to ions across multiple organs, forming permselective pores with isoform 1 favoring cations and isoform 2 favoring anions. In sweat glands and kidney's Henle's loop, it is crucial for sodium permeability, impacting sweat production and renal function.

Therapeutic significance:

Claudin-10's mutation leads to HELIX syndrome, marked by heat intolerance, anhidrosis, and electrolyte imbalance. Understanding Claudin-10's role could unveil new therapeutic strategies for managing HELIX syndrome and improving renal function and sweat production.